ERBB2 and breast cancer: Another human MoAb used in BC treatment is pertuzumab (Perjeta®) that inhibits the dimerization of HER-2 and HER-3 receptors; it is used in combination with trastuzumab as neoadjuvant therapy for BC at an early stage and, recently, also as adjuvant therapy to treat tumors in advanced stages (Figure 1 and Table 1) [30].